Isomorphic Labs, the artificial intelligence drug discovery company spun out of Alphabet, has raised $2 billion in a new funding round, according to Biopharma Dive. The financing underscores growing investor appetite for AI-driven biotech platforms that promise to accelerate the timeline and reduce the cost of bringing new medicines to market.
The round was led by existing backers, including a significant commitment from Alphabet itself, though specific breakdowns of investor participation were not disclosed. Isomorphic plans to use the capital to expand its computational platform and advance its internal pipeline of small-molecule drugs across multiple therapeutic areas.
Founded in 2021 by DeepMind CEO Demis Hassabis, the company aims to apply advanced machine learning techniques to predict protein structures and design drugs with higher precision. Its technology builds on AlphaFold, DeepMind’s breakthrough protein-folding AI, which has already been widely adopted in academic and pharmaceutical research.
The company has not disclosed a timeline for regulatory filings or clinical data, as its programs remain largely in preclinical stages. The fundraising arrives amid a broader surge in AI drug discovery investment, with several publicly traded peers seeing their valuations rise sharply in recent quarters.
Critics caution that the field still lacks robust clinical validation, and no AI-designed drug has yet completed late-stage trials. The hefty valuation of Isomorphic, which has no marketed products, reflects high expectations that may take years to materialize.